Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Natural Killer Cell Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT01178658
What this trial is testing

Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma

Who this might be right for
Non-Hodgkin Lymphoma
Seoul National University Hospital 42
Testing effectiveness (Phase 2)Study completedNCT01823198
What this trial is testing

Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Erythroid LeukemiaAcute Megakaryoblastic Leukemia+12 more
M.D. Anderson Cancer Center 63
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07457177
What this trial is testing

Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL

Who this might be right for
NK T-Cell Lymphoma
LIANG WANG 40
Early research (Phase 1)Looking for participantsNCT06690827
What this trial is testing

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN

Who this might be right for
AML (Acute Myeloid Leukemia)BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm)
Chongqing Precision Biotech Co., Ltd 30
Testing effectiveness (Phase 2)UnknownNCT02725996
What this trial is testing

By Using Adoptive Transfer of Autologous NK Cells to Prevent Recurrence of Hepatocellular Carcinoma After Curative Therapy

Who this might be right for
Hepatocellular Carcinoma
Southwest Hospital, China 140
Testing effectiveness (Phase 2)Ended earlyNCT05207722
What this trial is testing

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Who this might be right for
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Celularity Incorporated 1
Testing effectiveness (Phase 2)Study completedNCT01390402
What this trial is testing

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

Who this might be right for
LeukemiaChronic Myelogenous Leukemia
M.D. Anderson Cancer Center 6
Testing effectiveness (Phase 2)UnknownNCT03107962
What this trial is testing

Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma

Who this might be right for
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Mingzhi Zhang 20
Early research (Phase 1)Study completedNCT00161590
What this trial is testing

Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma

Who this might be right for
T-Cell LymphomaLymphoma, Non-Hodgkin's
Weill Medical College of Cornell University
Early research (Phase 1)Ended earlyNCT05385705
What this trial is testing

Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Who this might be right for
Breast Neoplasms
Vall d'Hebron Institute of Oncology 2
Early research (Phase 1)Study completedNCT00877110
What this trial is testing

Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Who this might be right for
NeuroblastomaBone Marrow, Sympathetic Nervous System
Memorial Sloan Kettering Cancer Center 71
Not applicableStudy completedNCT00934986
What this trial is testing

Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic Leukemia
Institut Paoli-Calmettes 70
Early research (Phase 1)UnknownNCT03619954
What this trial is testing

NK Cells Infusion for Advanced Malignancies

Who this might be right for
Immunotherapy
Anhui Provincial Hospital 50
Early research (Phase 1)Study completedNCT00569283
What this trial is testing

Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant

Who this might be right for
Cancer
Asan Medical Center 18
Testing effectiveness (Phase 2)UnknownNCT03987698
What this trial is testing

Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma

Who this might be right for
Renal Cell CarcinomaClear Cell Renal Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital 90
Early research (Phase 1)UnknownNCT05379647
What this trial is testing

Natural Killer (NK) Cell Therapy for B-Cell Malignancies

Who this might be right for
B-cell LymphomaB-cell Acute Lymphoblastic Leukemia
Zhejiang University 24
Not applicableEnded earlyNCT03152526
What this trial is testing

CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR

Who this might be right for
Acute Myelogenous Leukemia
Miltenyi Biotec B.V. & Co. KG 1
Testing effectiveness (Phase 2)Ended earlyNCT00450983
What this trial is testing

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Who this might be right for
Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes
Fred Hutchinson Cancer Center 1
Early research (Phase 1)Study completedNCT01212341
What this trial is testing

Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor

Who this might be right for
Malignant LymphomasSolid Tumors
Seoul National University Hospital 18
Early research (Phase 1)Study completedNCT02955550
What this trial is testing

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Celularity Incorporated 15
Next Page